Patent ID: 11944631
Assignee: INFINITY PHARMACEUTICALS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 0:
1. A method of treating a hematological cancer in a human subject in need thereof, comprising administering to the subject (S)-3-(1-((914-purin-6-yl)amino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one (Compound 1), or a pharmaceutically acceptable salt or hydrate thereof, concurrently with, prior to, or subsequent to 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl]piperazin-1-yl]-N-[[3-nitro-4-[[(tetrahydro-211-pyran-4-yl)ethyl]amino]phenyl]sulfonyl]-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide(ABT-199), or a pharmaceutically acceptable salt thereof;
wherein Compound 1, or a pharmaceutically acceptable salt or hydrate thereof, is administered at a dose of about 15 mg to about 75 mg;
wherein A13T-199, or a pharmaceutically acceptable salt thereof, is administered at a dose of about 10 mg to about 400 mg; and
wherein the hematological cancer is selected from the group consisting of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), CLL/SLL, indolent NHL (iNHL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), T-cell lymphoma (TCL), peripheral I-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL), follicular lymphoma (FL), and Richter's syndrome.